MovDisordV3, Main, Exploration, bibRecord, 003D89

Cabergoline versus levodopa monotherapy

Identifieur interne : 003D89 ( Main/Exploration ); précédent : 003D88; suivant : 003D90

Cabergoline versus levodopa monotherapy

Auteurs : Keith Wheatley [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Richard Gray [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 2004-06.

RBID : ISTEX:4FEBF3A9CC317189FADF03420AB09534017E3DBC

English descriptors

KwdEn :
- Antiparkinson Agents (economics), Antiparkinson Agents (therapeutic use), Cost-Benefit Analysis, Ergolines (economics), Ergolines (therapeutic use), Humans, Levodopa (economics), Levodopa (therapeutic use), Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (economics).
MESH :
- chemical , economics : Antiparkinson Agents, Ergolines, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Ergolines, Levodopa.
- drug therapy : Parkinson Disease.
- economics : Parkinson Disease.
- Cost-Benefit Analysis, Humans, Middle Aged.

Url:

https://api.istex.fr/document/4FEBF3A9CC317189FADF03420AB09534017E3DBC/fulltext/pdf

DOI: 10.1002/mds.20032

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cabergoline versus levodopa monotherapy</title>
<author><name sortKey="Wheatley, Keith" sort="Wheatley, Keith" uniqKey="Wheatley K" first="Keith" last="Wheatley">Keith Wheatley</name>
</author>
<author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
</author>
<author><name sortKey="Gray, Richard" sort="Gray, Richard" uniqKey="Gray R" first="Richard" last="Gray">Richard Gray</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4FEBF3A9CC317189FADF03420AB09534017E3DBC</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1002/mds.20032</idno>
<idno type="url">https://api.istex.fr/document/4FEBF3A9CC317189FADF03420AB09534017E3DBC/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003398</idno>
<idno type="wicri:Area/Istex/Curation">003398</idno>
<idno type="wicri:Area/Istex/Checkpoint">002770</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Wheatley K:cabergoline:versus:levodopa</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15197724</idno>
<idno type="wicri:Area/PubMed/Corpus">003423</idno>
<idno type="wicri:Area/PubMed/Curation">003423</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003537</idno>
<idno type="wicri:Area/Ncbi/Merge">000E61</idno>
<idno type="wicri:Area/Ncbi/Curation">000E61</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000E61</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Wheatley K:cabergoline:versus:levodopa</idno>
<idno type="wicri:Area/Main/Merge">005747</idno>
<idno type="wicri:Area/Main/Curation">003D89</idno>
<idno type="wicri:Area/Main/Exploration">003D89</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cabergoline versus levodopa monotherapy</title>
<author><name sortKey="Wheatley, Keith" sort="Wheatley, Keith" uniqKey="Wheatley K" first="Keith" last="Wheatley">Keith Wheatley</name>
<affiliation wicri:level="1"><country wicri:rule="url">Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, University of Birmingham, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
<orgName type="university">Université de Birmingham</orgName>
</affiliation>
</author>
<author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>City Hospital Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gray, Richard" sort="Gray, Richard" uniqKey="Gray R" first="Richard" last="Gray">Richard Gray</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit Birmingham</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2004-06">2004-06</date>
<biblScope unit="vol">19</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="733">733</biblScope>
<biblScope unit="page" to="734">734</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">4FEBF3A9CC317189FADF03420AB09534017E3DBC</idno>
<idno type="DOI">10.1002/mds.20032</idno>
<idno type="ArticleID">MDS20032</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (economics)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Cost-Benefit Analysis</term>
<term>Ergolines (economics)</term>
<term>Ergolines (therapeutic use)</term>
<term>Humans</term>
<term>Levodopa (economics)</term>
<term>Levodopa (therapeutic use)</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (economics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Ergolines</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Ergolines</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cost-Benefit Analysis</term>
<term>Humans</term>
<term>Middle Aged</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Midlands de l'Ouest</li>
</region>
<settlement><li>Birmingham</li>
</settlement>
<orgName><li>Université de Birmingham</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><noRegion><name sortKey="Wheatley, Keith" sort="Wheatley, Keith" uniqKey="Wheatley K" first="Keith" last="Wheatley">Keith Wheatley</name>
</noRegion>
<name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name>
<name sortKey="Gray, Richard" sort="Gray, Richard" uniqKey="Gray R" first="Richard" last="Gray">Richard Gray</name>
<name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
<name sortKey="Wheatley, Keith" sort="Wheatley, Keith" uniqKey="Wheatley K" first="Keith" last="Wheatley">Keith Wheatley</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D89 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003D89 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:4FEBF3A9CC317189FADF03420AB09534017E3DBC
   |texte=   Cabergoline versus levodopa monotherapy
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Cabergoline versus levodopa monotherapy

Cabergoline versus levodopa monotherapy

Source :

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.